a A Proud to be a Banner Health Center of Excellence

Studies Currently Enrolling

Studies for participants without memory loss

API Generation Study: A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease 

CAPI015A2201J: A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease.

Novartis Pharmaceuticals
Banner Alzheimer’s Institute
National Institute on Aging (NIA)
Alzheimer’s Association
Amgen

Condition: Individuals at increased risk

ClinicalTrials.gov identifier: NCT02565511 

Drug: CAD106 and CNP520

 

Ages Eligible for Study:

60-75 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The purpose of this study is to assess the effects of two investigational drugs, CAD106 and CNP520, when administered separately. This study is evaluating whether these drugs can slow down the onset and progression of clinical symptoms associated with Alzheimer’s disease in participants who are at an increased risk to develop symptoms based on their age and genetic status.

For more information: www.GenerationStudy.com   

 

GeneMatch

The GeneMatch program: part of the Alzheimer’s Prevention Registry that aims to identify a large group of people who are interested in participating in Alzheimer’s research studies or clinical trials based in part on genetic information.

Banner Alzheimer’s Institute

Condition

Individuals with normal memory and thinking who may be at increased risk for Alzheimer’s disease

ClinicalTrials.gov identifier: NCT02564692

 

 

Ages Eligible for Study:

55-75 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The primary purpose of GeneMatch is to advance Alzheimer’s research by helping scientists find enough qualified participants to launch new studies based in part on their genetic information. GeneMatch will provide interested individuals with a cheek swab kit in order to collect information on which copies of a gene (known as the APOE type allele) they have. Individuals who participate will not be told their genetic results, but they may be contacted about study opportunities in their area.

For more information about GeneMatch please visit: www.endALZnow.org/GeneMatch

 

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

H8A-MC-LZAZ/ADC-040-A4: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

Eli Lilly and Company

Condition: Cognition Disorders

ClinicalTrials.gov identifier: NCT02008357    

Drug: Solanezumab

 

Ages Eligible for Study:

65 to 85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The A4 study is a clinical trial for older individuals who have evidence of amyloid plaque build-up in their brains and may be at risk for memory loss and cognitive decline due to Alzheimer’s disease. The A4 study will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer’s disease, cognitive impairment or dementia. The intent is to slow memory and cognitive decline. The A4 study will also test whether anti-amyloid treatment can delay the progression of AD related brain injury on imaging and other biomarkers.

 

Brain Imaging, APOE & the Preclinical Course of Alzheimer’s Disease Study

ClinicalTrials.gov identifier: n/a

Ages Eligible for Study:

47 to 68 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

This study is sponsored by the National Institutes of Health (NIH) and is a long-term study that seeks to better understand the course of Alzheimer’s disease before clinical symptoms emerge. This brain imaging study, a collaboration with Mayo Clinic, will follow individuals indefinitely. The purpose is to observe the course of aging in participants with different genetic risk levels of developing different memory problems. The study includes visits every two years. Imaging visits include MRIs and PET scans. The study also includes optional lumbar punctures. Participants do not require a study partner.

 

Studies for participants with and without memory loss

Alzheimer’s Disease Core Center (ADCC)

Sponsor: University of Arizona
Collaborators: Banner Alzheimer’s Institute
Banner Sun Health Research Institute
Barrow Neurological Foundation
Mayo Clinic
National Institute on Aging (NIA)
National Institutes of Health (NIH)

Conditions:

Alzheimer’s Disease

Mild Cognitive Impairment

Age-Related Memory Disorders

ClinicalTrials.gov identifier: NCT01421420

 

 

Ages Eligible for Study:

40 years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The main objective of this research project is to provide a comprehensive clinical database of patients with Alzheimer's disease and other forms of dementia, individuals with mild cognitive impairment (MCI), and age-matched normal controls. The study will also attempt to identify cognitively normal individuals at genetically defined risk for Alzheimer’s disease through genetic screening.

All participants are seen annually. Autopsies to establish diagnoses in patients with dementia, patients with mild MCI, and cognitively normal elderly control subjects will also be conducted

 

Studies for participants with memory loss

221AD302: A Clinical Trial to Evaluate the Efficacy and Safety of the Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease

Biogen MA, Inc.

Condition: Mild Cognitive Impairment

ClinicalTrials.gov identifier: NCT02484547 

Drug: Aducanumab (BIIB037)

 

Ages Eligible for Study:

50 to 85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

The primacy objective of this study is to evaluate the effectiveness of monthly doses of aducanumab in slowing both functional and cognitive impairments in adults with Mild Cognitive Impairment. Changes in impairment will be measured using the scores of cognitive tests as compared with placebo. Additional objectives are to evaluate the long-term safety and tolerability profile and evaluate long-term effectiveness of aducanumab measured by numerous clinical assessments.

 

Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)

National Institute on Aging (NIA) and Johns Hopkins Bloomberg School of Public Health

ConditionAlzheimer’s disease

ClinicalTrials.gov identifier: NCT02346201

Drug: Methylphenidate

 

Ages Eligible for Study:

18+ years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

ADMET 2 is a six-month, placebo-controlled clinical trial sponsored by the National Institutes of Aging. The primary objective is to examine the efficacy of methylphenidate for the treatment of individuals with Alzheimer’s disease who also have clinically significant apathy. 

 

15-AVP-786-302: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type 

Avanir Pharmaceuticals, Inc.

ConditionAlzheimer’s disease

ClinicalTrials.gov identifier: NCT02442778  

Drug: AVP-786

 

Ages Eligible for Study:

50 to 90 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type. AVP-786 is a combination of two medications; one medication is a modified form of dextromethorphan called deuterated d6-dextromethorphan (d6-DM) and the other is quinidine (Q), given in a very low dose. The original form of dextromethorphan has been in use for over 50 years and is commonly used in cough syrup. Quinidine is one of the oldest prescription drugs available and is used at higher doses to help control irregular heartbeats. Patients will be enrolled in the study for approximately 16 weeks; with up to 4-week screening period and 12-week treatment period.

 

MK-8931-019: An Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer’s Disease (P07738) 

Merck Sharp & Dohme Corp.

Conditions:

Amnestic Mild Cognitive Impairment

Prodromal Alzheimer’s disease

ClinicalTrials.gov identifier: NCT01953601  

Drug: MK-8931

 

Ages Eligible for Study:

50 to 85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

This study is open to participants with a diagnosis of mild cognitive impairment and prodromal Alzheimer’s disease. The purpose of the study is to assess the efficacy of MK-8931 (oral medication at two different doses) compared to a placebo group in improvement of cognitive functioning. The length of the study is approximately two years. The study requires a study partner (spouse, adult child, family member, friend, or caregiver) who can answer questions about the participant’s memory performance. There are also two optional sub-studies.

 

AC-12-010: AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH AD)

Accera, Inc.

Condition: Alzheimer’s disease

ClinicalTrials.gov identifier: NCT01741194   

Drug: AC-1204

 

Ages Eligible for Study:

66 to 90 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer’s disease. The study accepts healthy volunteers with mild to moderate Alzheimer’s disease.

 

D5010C00009:  An Efficacy and Safety Study of AZD3293 in Early Alzheimer's Disease (AMARANTH)

AstraZeneca

Condition: Alzheimer’s disease

ClinicalTrials.gov identifier: NCT02245737   

Drug: AZD3293

 

Ages Eligible for Study:

55 to 85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

The purpose of this study is to assess the efficacy and safety of AZD3293 compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will test the hypothesis that AZD3293 is a disease-modifying treatment for patients with early Alzheimer´s disease, defined as the continuum of patients with Moderate Cognitive Impairment (MCI) due to Alzheimer’s disease and patients diagnosed with mild dementia of the Alzheimer´s type, as measured by change from baseline in the Clinical dementia Rating-Sum of Boxes score at week 104 in each of the two AZD3293 treatment groups compared with placebo.